Key Finding
Electroacupuncture at ST36 reduced demyelination and inflammation in EAE mice while increasing populations of neural, hematopoietic, and mesenchymal stem cells, suggesting stem cell regulation as a potential therapeutic mechanism.
Researchers investigated whether electroacupuncture (a form of acupuncture using mild electrical stimulation) could help treat multiple sclerosis (MS) by studying its effects on an animal model of the disease. Multiple sclerosis is an autoimmune condition where the immune system attacks the protective covering of nerves, causing inflammation and various neurological symptoms.
The study used mice with experimental autoimmune encephalomyelitis (EAE), which mimics human MS. Researchers applied electroacupuncture to the ST36 acupoint (known as Zusanli in traditional Chinese medicine, located on the lower leg) daily for 28 days starting immediately after disease induction. They compared treated mice with untreated disease models and healthy controls.
The results showed promising effects. Mice receiving electroacupuncture at ST36 experienced less nerve damage, reduced inflammation in the central nervous system, lower clinical disease scores, and less weight loss compared to untreated mice. Additionally, the treatment appeared to increase populations of three important types of stem cells: neural stem cells (which can become brain cells), hematopoietic stem cells (which produce blood cells), and mesenchymal stem cells (which support tissue repair).
For patients with MS, this research suggests electroacupuncture might offer benefits beyond symptom relief by potentially supporting the body's natural repair mechanisms through stem cell regulation. While these are animal study results and human trials are needed, the findings add to growing evidence that acupuncture may provide meaningful therapeutic benefits for autoimmune neurological conditions. If you're considering acupuncture for MS or related conditions, consult with a licensed acupuncturist experienced in treating neurological disorders.
This study evaluated electroacupuncture (EA) at ST36 in experimental autoimmune encephalomyelitis (EAE), the standard murine model for multiple sclerosis. EAE mice received daily EA treatment at Zusanli (ST36) for 28 days post-immunization. Outcomes included clinical scoring, weight monitoring, histological assessment of demyelination and inflammatory infiltration, and quantification of neural stem cells (NSCs), hematopoietic stem cells (HSCs), and mesenchymal stem cells (MSCs).
Results demonstrated that EA at ST36 significantly reduced CNS demyelination and inflammatory cell infiltration, correlating with decreased clinical scores and attenuated weight loss compared to untreated EAE controls. Notably, EA treatment increased proportions of NSCs, HSCs, and MSCs relative to disease controls, suggesting a stem cell-mediated therapeutic mechanism.
Clinical relevance: This research provides mechanistic evidence for EA's immunomodulatory and neuroprotective effects in autoimmune demyelinating disease, potentially mediated through stem cell regulation. While promising, translation to clinical MS management requires human trials. Consider EA at ST36 as adjunctive therapy for autoimmune neurological conditions, particularly where stem cell mobilization may support tissue repair and immune regulation.
Browse our directory of verified licensed practitioners near you.
Find a practitioner โ๐ TENS therapy at 10 Hz with sacral electrode placement significantly reduced urinary and fecal incontinence in pediatric patients with non-neurological pelvic floor dysfunctions, particularly when combined with biofeedback or behavioral therapy.
๐ Combined electroacupuncture and methotrexate treatment synergistically reduced psoriatic inflammation more effectively than either therapy alone by rebalancing Th17/Treg immune responses and suppressing NF-ฮบB activation.
๐ All three dry eye disease patients showed significant improvements in ocular fatigue and dryness after only 3-4 days of electroacupuncture treatment, with sustained results at 4-week follow-up.